- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05908344
Frequen-ZZZ SleepPad Investigational Device POC
Use of the Frequen-ZZZ Sleep Pad to Increase Restorative Sleep: A Proof-of-Concept Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
State College, Pennsylvania, United States, 16802
- The Pennsylvania State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent is obtained from the subject.
- Subject is an English speaker and reader. They are able to understand the procedures related to the study.
- Subject is 40-65 years of age at enrollment (by self report at Screening & verified with photo ID at full Consent)
- Subject is not engaged in rotating or nocturnal shift employment (by self-report at Screening)
- Subject is living independently (by self-report and/or according to their status at a community living facility)
- Subject's personal residence is equipped with functional WiFi and subject is willing to permit study device connection to their WiFi (by self-report at Screening)
- Insomnia Severity Index score of ≥8 at enrollment (based on self-administration at screening)
- Willing to refrain from initiating new, sleep-directed interventions (e.g. medication; behavioral) that are not a part of this study protocol for the duration of study participation (by self-report)
- Willing to refrain from all nicotine use for the duration of participation (by self-report)
- Willing to refrain from pet access to the bed or sleeping space for the duration of participation (by self-report)
- Regularly sleeping on a non-water bed (by self-report)
- Has and uses own smart phone or tablet device, and is willing to continue to use personal device daily for study purposes (by self-report)
Exclusion Criteria:
- Diagnosed with a sleep disorder (by self-report)
- Has an implanted medical device (e.g., pacemaker, cochlear; by self-report)
- Diagnosed serious mental/neurologic health disorder or substance use disorder (e.g., autism, psychosis, depression/bipolar, dementia; by self-report)
- Personal health history of epilepsy or traumatic brain injury (by self-report)
- Taking any physician-directed pharmacologic intervention for sleep or actively engaged in a clinically-validated course of therapy (including behavioral therapy for sleep; by self-report)
- Diagnosed hydration problems or taking prescribed diuretic medication (by self-report)
- Pregnant, breast-feeding, or planning to become pregnant during the study participation period (by self-report)
- History of negative reaction to acupuncture (by self-report)
- Recreational use of illicit substances in the past month (by self-report)
- Any nicotine use in the past 3 months (by self-report)
- History of sensitivity to, or considers oneself to be uniquely sensitive to, radio-frequency (by self-report)
- Was previously engaged in this research as a randomized participant
- If a participant does not live within a reasonable commutable distance from the Penn State University - University Park campus (i.e. ~20min) to accommodate off-site study visits, then they must be willing to accept the costs and responsibilities of coming to campus (15-17 visits) in order to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Activated Sleep Pad controller
Treatment dosing is under participant control, by physical proximity/orientation to the Sleep Pad pad portion of the Sleep Pad system, and by a manually operated power button on an activated bedside controller portion of the Sleep Pad system.
Dosing is pre-set at a stable level across all participants.
Dosing occurs throughout a participant's typical nocturnal sleep period, nightly, unless manually paused by the participant.
|
The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential.
An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect.
The field potentials generated by the pad are hypothesized to have benefit for sleep.
|
|
Sham Comparator: Deactivated Sleep Pad controller
Use of the Sleep Pad system is consistent with the Experimental arm, excepting that a deactivated bedside controller portion of the Sleep Pad system is used.
|
The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential.
An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Sleep Architecture
Time Frame: The later viable night of two recordings: At the end of Phase 1 - Week 2 or Phase 1 - Week 3, and At the end of Phase 2 - Week 2 or Phase 2 - Week 3. Sleep stage minutes (relative to Latency to Persistent Sleep, Edinger et al. 2013).
|
Quantity of each sleep stage defined by the American Academy of Sleep Medicine (NREM1, NREM2, NREM3, and REM), measured by clinically standard elements of Polysomnography and scored by a Registered Polysomnographic Technologist. Note: Randomization to Active or Sham during Phase 1 or Phase 2 occurred at the end of Baseline week. |
The later viable night of two recordings: At the end of Phase 1 - Week 2 or Phase 1 - Week 3, and At the end of Phase 2 - Week 2 or Phase 2 - Week 3. Sleep stage minutes (relative to Latency to Persistent Sleep, Edinger et al. 2013).
|
|
Change in Sleep Architecture
Time Frame: The later viable night of two recordings: At the end of Phase 1 - Week 2 or Phase 1 - Week 3, and At the end of Phase 2 - Week 2 or Phase 2 - Week 3. Sleep stage percentage (relative to Latency to Persistent Sleep, Edinger et al. 2013).
|
Percentage of each sleep stage defined by the American Academy of Sleep Medicine (NREM1, NREM2, NREM3, and REM), measured by clinically standard elements of Polysomnography and scored by a Registered Polysomnographic Technologist. Note: Randomization to Active or Sham during Phase 1 or Phase 2 occurred at the end of Baseline week. |
The later viable night of two recordings: At the end of Phase 1 - Week 2 or Phase 1 - Week 3, and At the end of Phase 2 - Week 2 or Phase 2 - Week 3. Sleep stage percentage (relative to Latency to Persistent Sleep, Edinger et al. 2013).
|
|
Change in Insomnia Symptoms
Time Frame: Sum ISI score near end of Phase 1 (study wks2-4) and near end of Phase 2 (study wks6-8).
|
Self-reported score on the Insomnia Severity Index (ISI; 0-28) e-survey, where a higher score indicates worse/more Insomnia symptoms.
|
Sum ISI score near end of Phase 1 (study wks2-4) and near end of Phase 2 (study wks6-8).
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kunasan
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Christoph NissenRecruitingInsomnia | Insomnia Chronic | Insomnia Disorder | Insomnia, Primary | Insomnia Type; Sleep Disorder | Insomnia Disorders | Insomnia, NonorganicSwitzerland
-
University of PennsylvaniaPatient-Centered Outcomes Research InstituteNot yet recruitingInsomnia | Chronic Insomnia | Insomnia Disorder | Chronic Insomnia DisorderUnited States
-
National Yang Ming UniversityBened Biomedical Co., Ltd.Recruiting
-
Leiden University Medical CenterCompleted
-
Shanghai Haiyan Pharmaceutical Technology Co.,...Active, not recruiting
-
Weill Medical College of Cornell UniversityMARPACCompleted
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLC; National Sleep FoundationUnknownInsomniaUnited States
-
Posit Science CorporationUniversity of California, San FranciscoCompleted
-
University of UtahNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Minneapolis Veterans Affairs Medical CenterWithdrawn
Clinical Trials on Activated Sleep Pad system (Frequen-ZZZ)
-
LifeSeasons Inc.KGK Science Inc.Completed
-
National Institute of Allergy and Infectious Diseases...Terminated